REGN up +2.42% percent Today $REGN High is at 404.77 and the Low 395.20 with current volume of 167,953.
Recent News posted below.
Regeneron Pharmaceuticals REGN other info.
http://investorshangout.com/Regeneron-Pharmac...EGN-55275/
REGN Regeneron Pharmaceuticals Recent Headline News
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 41.04 (+0.99), REGN: 405.48 (+10.28), NVS: 94.42 (+0.47)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 307.60 (+2.17), VRTX: 111.52 (+0.18), GILD: 101.35 (-0.71), ALXN: 190.44 (+1.68), AMGN: 159.70 (+2.02), IBB: 291.41 (+3.24), REGN: 405.48 (+10.28), CELG: 105.30 (+1.25)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 101.35 (-0.71), AMGN: 159.70 (+2.02), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals
at Investor's Business Daily - Thu Nov 13, 7:02AM CST
With the market in confirmed uptrend and stock indices approaching new highs, focusing on companies with the best fundamentals, such as Regeneron Pharmaceuticals, is a ticket to winners that are likely to outperform the market. Today's Screen Of The...
JPM: 60.12 (-0.16), LNKD: 225.19 (-8.70), SFY: 6.32 (-0.21), CYBR: 43.50 (-0.87), FB: 75.17 (+0.29), ALXN: 190.44 (+1.68), TGT: 67.58 (-0.55), DATA: 85.52 (+0.69), TWTR: 40.90 (-0.95), PANW: 111.46 (+0.68), REGN: 405.48 (+10.28)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 212.98 (+14.33), ABBV: 64.94 (+0.94), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 111.52 (+0.18), GILD: 101.36 (-0.70), ACHN: 13.91 (-0.06), DNDN: 0.12 (+0.01), AMGN: 159.70 (+2.02), ABBV: 64.94 (+0.94), REGN: 405.48 (+10.28)
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.16 (+0.05), DHI: 24.47 (+0.09), AMZN: 321.81 (-6.01), TSLA: 256.24 (-2.44), KR: 58.21 (+0.50), SWY: 34.83 (-0.02), CLX: 100.31 (+0.19), XOM: 94.46 (-0.63), FCAU: 12.43 (+0.03), INO: 9.92 (-1.08), WHR: 175.67 (+2.40), T: 35.76 (-0.14), ISIS: 49.43 (+0.42), VALE: 8.85 (-0.02), EOG: 96.51 (-1.65), HAWK: 36.56 (+0.09), SHW: 240.29 (+0.64), VZ: 51.32 (-0.18), TOL: 33.69 (-0.03), REGN: 405.48 (+10.28), KELYA: 15.42 (unch), BABA: 114.64 (-0.46)
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.47 (+0.09), TSLA: 256.24 (-2.44), AMZN: 321.81 (-6.01), CY: 9.97 (-0.07), XOM: 94.46 (-0.63), KEX: 103.40 (-1.35), LRN: 12.83 (-0.26), BWLD: 161.22 (-1.45), ADBE: 70.72 (-0.70), GTLS: 42.46 (-0.56), TWX: 79.96 (+0.21), WHR: 175.67 (+2.40), T: 35.76 (-0.14), LYB: 87.19 (-1.14), ISIS: 49.43 (+0.42), CMG: 663.14 (-6.66), EOG: 96.51 (-1.65), HAWK: 36.56 (+0.09), SHW: 240.29 (+0.64), VZ: 51.32 (-0.18), DOW: 50.96 (-0.41), REGN: 405.48 (+10.28), KELYA: 15.42 (unch), CBS: 53.26 (-0.15)
Asthma treatment passes trial
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring asthma attacks. Based...
SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 386.96 (+0.92), YHOO: 51.36 (-0.39), AMZN: 321.80 (-6.02), BIIB: 307.60 (+2.17), VRTX: 111.42 (+0.08), FEYE: 33.28 (-0.52), LNKD: 225.19 (-8.70), EBAY: 54.72 (+0.36), GILD: 101.37 (-0.69), AMGN: 159.70 (+2.02), ABBV: 64.95 (+0.95), REGN: 405.48 (+10.28), CELG: 105.30 (+1.25)
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN)
at The Street - Tue Nov 11, 8:51AM CST
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a momo momentum candidate
REGN: 405.48 (+10.28)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.85 (+0.78), AZN: 71.98 (-0.87), AMGN: 159.70 (+2.02), TEVA: 57.86 (+0.79), THRX: 13.32 (+0.09), GSK: 45.88 (+0.14), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28), NVS: 94.42 (+0.47)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.36 (+0.06), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)
After Yesterday's Rally of 2.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 10, 4:06PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $376.54 to a high of $386.86. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $381.00 on volume of 539,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 405.48 (+10.28)
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
REGN: 405.48 (+10.28)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.15 (-0.10), SNY: 47.17 (+0.49), GNW: 9.36 (-0.05), REGN: 405.48 (+10.28)
Regeneron updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:09AM CST
REGN: 405.48 (+10.28)
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis
DoctoRx - at Seeking Alpha - Thu Nov 06, 7:32AM CST
AMGN: 159.70 (+2.02), SNY: 47.17 (+0.49), REGN: 405.18 (+9.98)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 90.68 (+0.56), AMGN: 159.70 (+2.02), SNY: 47.17 (+0.49), REGN: 405.18 (+9.98)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Wed Nov 05, 10:24AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 307.60 (+2.17), MNST: 109.10 (+1.18), ATI: 32.38 (-0.47), MON: 118.91 (-0.06), GMCR: 154.92 (+0.65), VMC: 66.10 (-0.21), EMR: 63.47 (-0.15), WDC: 97.51 (-0.90), VRSN: 60.68 (+0.01), URBN: 30.91 (+0.06), FSLR: 47.77 (-0.72), DE: 86.08 (-1.44), EXPE: 87.69 (-0.24), FLR: 63.77 (-0.93), FLS: 65.80 (-0.33), X: 35.55 (-0.69), ROK: 109.50 (-0.62), REGN: 405.18 (+9.98), MA: 84.03 (-0.02)
Recent News posted below.
Regeneron Pharmaceuticals REGN other info.
http://investorshangout.com/Regeneron-Pharmac...EGN-55275/
REGN Regeneron Pharmaceuticals Recent Headline News
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 41.04 (+0.99), REGN: 405.48 (+10.28), NVS: 94.42 (+0.47)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 307.60 (+2.17), VRTX: 111.52 (+0.18), GILD: 101.35 (-0.71), ALXN: 190.44 (+1.68), AMGN: 159.70 (+2.02), IBB: 291.41 (+3.24), REGN: 405.48 (+10.28), CELG: 105.30 (+1.25)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 101.35 (-0.71), AMGN: 159.70 (+2.02), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals
at Investor's Business Daily - Thu Nov 13, 7:02AM CST
With the market in confirmed uptrend and stock indices approaching new highs, focusing on companies with the best fundamentals, such as Regeneron Pharmaceuticals, is a ticket to winners that are likely to outperform the market. Today's Screen Of The...
JPM: 60.12 (-0.16), LNKD: 225.19 (-8.70), SFY: 6.32 (-0.21), CYBR: 43.50 (-0.87), FB: 75.17 (+0.29), ALXN: 190.44 (+1.68), TGT: 67.58 (-0.55), DATA: 85.52 (+0.69), TWTR: 40.90 (-0.95), PANW: 111.46 (+0.68), REGN: 405.48 (+10.28)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 212.98 (+14.33), ABBV: 64.94 (+0.94), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 111.52 (+0.18), GILD: 101.36 (-0.70), ACHN: 13.91 (-0.06), DNDN: 0.12 (+0.01), AMGN: 159.70 (+2.02), ABBV: 64.94 (+0.94), REGN: 405.48 (+10.28)
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.16 (+0.05), DHI: 24.47 (+0.09), AMZN: 321.81 (-6.01), TSLA: 256.24 (-2.44), KR: 58.21 (+0.50), SWY: 34.83 (-0.02), CLX: 100.31 (+0.19), XOM: 94.46 (-0.63), FCAU: 12.43 (+0.03), INO: 9.92 (-1.08), WHR: 175.67 (+2.40), T: 35.76 (-0.14), ISIS: 49.43 (+0.42), VALE: 8.85 (-0.02), EOG: 96.51 (-1.65), HAWK: 36.56 (+0.09), SHW: 240.29 (+0.64), VZ: 51.32 (-0.18), TOL: 33.69 (-0.03), REGN: 405.48 (+10.28), KELYA: 15.42 (unch), BABA: 114.64 (-0.46)
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.47 (+0.09), TSLA: 256.24 (-2.44), AMZN: 321.81 (-6.01), CY: 9.97 (-0.07), XOM: 94.46 (-0.63), KEX: 103.40 (-1.35), LRN: 12.83 (-0.26), BWLD: 161.22 (-1.45), ADBE: 70.72 (-0.70), GTLS: 42.46 (-0.56), TWX: 79.96 (+0.21), WHR: 175.67 (+2.40), T: 35.76 (-0.14), LYB: 87.19 (-1.14), ISIS: 49.43 (+0.42), CMG: 663.14 (-6.66), EOG: 96.51 (-1.65), HAWK: 36.56 (+0.09), SHW: 240.29 (+0.64), VZ: 51.32 (-0.18), DOW: 50.96 (-0.41), REGN: 405.48 (+10.28), KELYA: 15.42 (unch), CBS: 53.26 (-0.15)
Asthma treatment passes trial
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring asthma attacks. Based...
SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 386.96 (+0.92), YHOO: 51.36 (-0.39), AMZN: 321.80 (-6.02), BIIB: 307.60 (+2.17), VRTX: 111.42 (+0.08), FEYE: 33.28 (-0.52), LNKD: 225.19 (-8.70), EBAY: 54.72 (+0.36), GILD: 101.37 (-0.69), AMGN: 159.70 (+2.02), ABBV: 64.95 (+0.95), REGN: 405.48 (+10.28), CELG: 105.30 (+1.25)
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN)
at The Street - Tue Nov 11, 8:51AM CST
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a momo momentum candidate
REGN: 405.48 (+10.28)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.85 (+0.78), AZN: 71.98 (-0.87), AMGN: 159.70 (+2.02), TEVA: 57.86 (+0.79), THRX: 13.32 (+0.09), GSK: 45.88 (+0.14), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28), NVS: 94.42 (+0.47)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.36 (+0.06), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)
After Yesterday's Rally of 2.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 10, 4:06PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $376.54 to a high of $386.86. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $381.00 on volume of 539,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 405.48 (+10.28)
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
REGN: 405.48 (+10.28)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.15 (-0.10), SNY: 47.17 (+0.49), GNW: 9.36 (-0.05), REGN: 405.48 (+10.28)
Regeneron updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:09AM CST
REGN: 405.48 (+10.28)
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis
DoctoRx - at Seeking Alpha - Thu Nov 06, 7:32AM CST
AMGN: 159.70 (+2.02), SNY: 47.17 (+0.49), REGN: 405.18 (+9.98)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 90.68 (+0.56), AMGN: 159.70 (+2.02), SNY: 47.17 (+0.49), REGN: 405.18 (+9.98)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Wed Nov 05, 10:24AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 307.60 (+2.17), MNST: 109.10 (+1.18), ATI: 32.38 (-0.47), MON: 118.91 (-0.06), GMCR: 154.92 (+0.65), VMC: 66.10 (-0.21), EMR: 63.47 (-0.15), WDC: 97.51 (-0.90), VRSN: 60.68 (+0.01), URBN: 30.91 (+0.06), FSLR: 47.77 (-0.72), DE: 86.08 (-1.44), EXPE: 87.69 (-0.24), FLR: 63.77 (-0.93), FLS: 65.80 (-0.33), X: 35.55 (-0.69), ROK: 109.50 (-0.62), REGN: 405.18 (+9.98), MA: 84.03 (-0.02)
